The purpose of this trial is to look at the effectiveness of patients being switched from haldol, seroquel or zyprexa to biweekly risperidone injections.

Condition	Treatment or Intervention	Phase
Schizophrenia	Drug: risperidone, quetiapine, olanzapine, haloperidol	Phase III

Further Study Details: 

Expected Total Enrollment:  141

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Diagnosis of schizophrenia according to the DSM IV criteria (295.10, 295.20, 295.30, 295.60, 295.90);
• Currently treated with either oral haloperidol, quetiapine fumarate, or olanzapine for 4 months prior to trial entry;
• PANSS score of <80; on each of the following PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content, the score is < 4;
• Subject with a body mass index < 35 at screening

Arkansas
      Clinical Studies Center, Little Rock,  Arkansas,  72205,  United States
California
      Cedars-Sinai Medical Center, Los Angeles,  California,  90048,  United States
      Affiliated Research Institute, San Diego,  California,  92108,  United States
      Sharp Mesa-Vista Hospital, San Diego,  California,  92123,  United States
      Comprehensive NeuroScience-IPR, Cerritos,  California,  90703,  United States
      BMR HealthQuest, Glendale,  California,  91206,  United States
District of Columbia
      Comprehensive NeuroScience, Inc, Washington,  District of Columbia,  20016,  United States
Florida
      ICSL - Clinical Studies, Melbourne,  Florida,  32935,  United States
      Berma Research Group, Hialeah,  Florida,  33016,  United States
Georgia
      Carman Research, Smyrna,  Georgia,  30080,  United States
Hawaii
      Hawaii Clinical Research Center, Honolulu,  Hawaii,  96826,  United States
Illinois
      Alexian Brothers Behavior Health Hospital, Hoffman Estates,  Illinois,  60194,  United States
Louisiana
      LSU Behavioral Research Institute, New Orleans,  Louisiana,  70112,  United States
Maryland
      Centers for Behavioral Health, Rockville,  Maryland,  20850,  United States
New Jersey
      ClinSearch Inc., Kenilworth,  New Jersey,  07033,  United States
      Comprehensive Clinical Research,, Clementon,  New Jersey,  08021,  United States
New York
      Neurobehavior Research Inc., Lawrence,  New York,  11559,  United States
      Neuropsych Research Associates, New York,  New York,  10128,  United States
      Manhattan Psychiatric Center, New York,  New York,  10035,  United States
      Behavioral Medical Research, Staten Island,  New York,  10305,  United States
Oklahoma
      IPS Research, Oklahoma City,  Oklahoma,  73103,  United States
Pennsylvania
      VA Medical Center, Coatesville,  Pennsylvania,  19320-2096,  United States
South Carolina
      South Carolina VA Medical Center, Charleston,  South Carolina,  29401-5799,  United States
Tennessee
      Clinical Research Services @Tennessee Christian Medical Center, Madison,  Tennessee,  37115,  United States
Texas
      Community Clinical Research, Inc, Austin,  Texas,  78756,  United States
      St. Paul Medical Center, Dallas,  Texas,  75235,  United States
      Med Labs Research of Houston, Inc., Houston,  Texas,  77057,  United States
      Univ. of Texas Health Science Center at San Antonio, San Antonio,  Texas,  78229-3900,  United States
Virginia
      Medical College of Virginia, Richmond,  Virginia,  23298,  United States

Study ID Numbers:  RIS-USA-259
Record last reviewed:  January 2003
Last Updated:  October 13, 2004
Record first received:  May 2, 2002
ClinicalTrials.gov Identifier:  NCT00034775
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08